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Su1002
Cutaneous Vasculitis in a Patient With Crohn's Disease Treated With
Adalimumab
Alex C. Faria, Alan C. Moss, Alexandre W. Souza, Giovanni Viana, Danilo Odashiro,
Didia B. Cury
Background: Anti-TNF therapies have been rarely associated with cutaneous vasculitis.
Herein we describe a case of cutaneous vasculitis in a patient receiving adalimumab therapy.
Case presentation: A 28- year- old woman with a history of Crohn's disease refractory to
conventional therapy started treatment with adalimumab in 2012. She had no prior history
of cutaneous manifestations. After 24 months of adalimumab therapy, she reported raised
lesions on her legs (Figure 1). She denied any accompanying as joint pain or constitutional
symptoms. Laboratory tests, including CRP, ESR, blood counts, urinalysis, and complement,
were normal. ANA, anti-ENA, RF, cANCA, pANCA, anti-phospholipid and cryoglobulins
were negative. A skin biopsy described leukocytoclastic vasculitis in the post-capillary ven-
ules. This finding was strongly suggestive of cutaneous drug-induced vasculitis (Figure 2).
Five days after the onset of vasculitis, the adalimumab was withdrawn and the patient started
on high dose prednisolone (60mg/day). However, only moderate response was observed,
so colchicine was added at 0.5mg TID. The cutaneous lesions then resolved within 3 days
of colchicine therapy, allowing steroid tapering. Conclusion: This case report illustrates
cutaneous vasculitis as a potential association with anti-TNF therapy. In addition to stopping
the suspected drug, colchicine may be helpful in patients refractory to high-dose glucocorti-
coids.
Su1004
Using Search Engine Query Data to Explore Epidemiology of Common
Gastrointestinal Symptoms
Benjamin Hassid, Benjamin Breyer, Mohannad Awad, Justin L. Sewell, Lukejohn Day
Background Internet search activities are an increasingly used tool in medical research, and
search data has been recognized as a promising source of medical information by the Institute
of Medicine. One particularly fruitful source of information has been Google Trends, a free
S-441 AGA Abstracts
publically accessible portal for analyzing trends in the Google search engine. This resource
has been used to understand the epidemiology of multiple disease states, including communi-
cable and non-communicable diseases. To date, no studies have examined Google search
data in relation to common gastrointestinal (GI) symptoms. Our aims were to compare
changes to search volume for common GI symptoms to clinical data sets. Methods: Using
Google Trends, we recorded relative changes to search volume for searches related to
dysphagia, vomiting, and diarrhea in the United States between January 2008 and January
2011. At the same time, we queried the National Inpatient Sample (NIS) during that same
time period and identified cases with ICD-9-CM codes related to these symptoms as the
primary diagnosis for the same time period. We also queried the National Hospital Ambula-
tory Medical Care Survey (NHAMCS) and identified cases associated with these same symp-
toms as the primary reason for visit for the same period. We calculated Pearson correlation
coefficients to assess correlation between changes to Google search volume and changes to
number of cases in the NIS and NHAMCS datasets during this timeframe. Results: Changes
to Google search volume for all three symptoms correlated significantly with NIS output
(dysphagia- r = 0.5, P= 0.002; diarrhea- r = 0.79, P <0.001; vomiting- r = 0.76, P <0.001).
Both Google and NIS data showed that the prevalence of all three symptoms rose during
the time period studied (2008-2010). On the other hand, the NHAMCS data trends during
this time period did not correlate significantly with either the NIS or the Google data for
any of the three symptoms studied. Conclusion: Changes to the population burden of
chronic GI symptoms may be easily tracked by monitoring changes to Google search engine
query volume over time, which correlated well with a large inpatient clinical dataset for
three common GI symptoms. During the time frame examined, the burden of dysphagia,
diarrhea, and vomiting appeared to rise. The outpatient dataset that we examined did not
correlate with either of the other datasets, likely related to its relatively small sample size.
Its ease of makes search engine query data a powerful tool in furthering our understanding
of the population burden of common symptoms, and since some who experience illness do
not seek medical attention, data of this type may shed light on dimensions of disease that
exist outside of a standard medical context.
Su1005
Intestinal Ultrasound Accurately Assesses Disease Activity in Inflammatory
Bowel Disease When Compared to Faecal Calprotectin
Neel Heerasing, Anil Asthana, Miles Sparrow, Simon Jakobovits, Peter R. Gibson, Antony
Friedman
Introduction Current guidelines recommend a treat to target approach in the management
of patients with inflammatory bowel disease (IBD) utilising objective measures of disease
activity. Faecal calprotectin is a non-invasive biomarker which has been shown to be a
surrogate marker for mucosal healing. However, calprotectin has significant limitations
including a lack of information regarding disease location, inter-patient variability and
moderate rates of both false negative and positive results. Intestinal ultrasound (IUS) is a
non-invasive imaging modality which has the ability to provide information on both disease
activity and location. There is a paucity of data comparing the accuracy of IUS to calprotectin
results. Aim To assess the accuracy of IUS compared to calprotectin levels in evaluating
disease activity in IBD. Methods A prospective IUS database for all imaging is maintained
at the Alfred Hospital. All patients with an IUS and faecal calprotectin performed within 7
days of each other in 2014 were enrolled. C-reactive protein (CRP) values were also analysed
with a CRP <3mg/L considered normal. IUS was performed by one of two IBD gastroenterolo-
gists with expertise in IUS. Statistical analyses were undertaken to assess the accuracy of
IUS using different thresholds for calprotectin including 30µg/g, 50µg/g, 100µg/g and 250µg/
g. Results The database included 139 patients (47% females) with the majority having
Crohn's disease (86%). Forty-eight IUS patients had matched faecal calprotectin levels.
Sensitivities, specificities, positive (PPV) and negative predictive values (NPV) are shown in
Table 1. For each threshold, IUS had very high negative predictive values. Conversely, IUS
had a high positive predictive value only when calprotectin levels exceeded 250µg/g. 107
patients undergoing an IUS had a matched CRP measured with 7 days of the scan. 45
patients had an elevated CRP. The sensitivity and specificity of CRP with positive IUS
findings were 65% and 68% respectively. The PPV and NPV of CRP were 49% and 80%
respectively. 35 patients had both matched calprotectin and CRP and in this group, all
patients (n=6) with calprotectin <30 and CRP <3 had negative IUS findings. The sensitivity
and specificity of calprotectin & CRP with positive IUS findings were 73% and 85% respec-
tively with the corresponding PPV and NPV being 79% and 81%. Conclusion This study
demonstrates the accuracy of IUS in assessing disease activity when compared to faecal
calprotectin. IUS has the additional benefits of being able to provide information regarding
disease location and complications such as strictures and fistulae. This also study also shows
that CRP is an inferior biomarker to both calprotectin and IUS. The combination of IUS
and faecal calprotectin are ideal non-invasive tools to monitor disease activity in IBD as a
replacement for colonoscopy.
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